Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
ID: 350883Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350883

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-036.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases under the R01 grant mechanism, which does not allow clinical trials. This initiative aims to support research projects that collect critical data to inform future clinical trials and observational studies, focusing on non-interventional studies that assess disease symptoms, progression, and patient outcomes. The funding, capped at $475,000 over a maximum of four years, is open to a diverse range of applicants, including higher education institutions and nonprofit organizations, with application submissions starting on February 4, 2024, and continuing through late 2026. For further details, applicants can reach out to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-036.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-036.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO), PAR-24-036, targeting Clinical Observational (CO) Studies in musculoskeletal, rheumatic, and skin diseases. The primary aim of this initiative is to secure applications for Research Project Grants (R01) that will collect data to design future clinical trials and observational studies. The emphasis is on non-interventional studies that gather information on disease symptoms, progression stages, and patient outcomes vital for future clinical research. Eligible applicants include higher education institutions, nonprofits, and various levels of government. Funding is capped at $475,000 over a maximum four-year project period, with stringent adherence to submission requirements highlighted. Key deadlines include submission openings on February 4, 2024, with multiple application cycles running through late 2026. The review process emphasizes the significance, innovation, and overall impact of proposed studies, requiring emphasis on diversity among participant demographics. The NOFO encourages the incorporation of telehealth, digital outcomes, and wearable devices in observational studies, ultimately striving to enhance clinical research around chronic diseases impacting largely diverse populations.
    Similar Opportunities
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases under the R01 Research Project Grant program. This initiative aims to support observational studies that gather critical data to inform future clinical research, focusing on understanding disease symptoms, progression, participant recruitment strategies, and potential biomarkers. The funding opportunity is significant for enhancing research outcomes in health fields related to these diseases, with applicants eligible to request up to $475,000 over four years. Key deadlines include an application submission start date of February 4, 2025, and a final expiration date of November 3, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Clinical Trial Grants (R61) to support research in arthritis and musculoskeletal and skin diseases. This funding opportunity aims to facilitate short-term, interventional studies that address critical research questions, particularly those evaluating drug efficacy in rare diseases, without requiring preliminary data. Grants can provide up to $600,000 over three years, with applications due by November 2, 2026. Interested applicants are encouraged to consult with NIH staff during the application process and can find additional information at NIH Grants or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)," aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that utilize well-characterized patient cohorts, infrastructure, data, and biological samples, while aligning with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). With an estimated total program funding of $600,000 and the expectation of awarding two grants, potential applicants are advised to begin developing collaborations and project proposals in advance of the official solicitation, which is expected to be published in early 2026. For further inquiries, interested parties may contact Dr. Heiyoung Park at Heiyoung.Park@nih.gov or by phone at 301-594-5032.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that align with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), utilizing well-characterized patient cohorts, infrastructure, data, and biological samples from parent studies. With an estimated total program funding of $2 million and an expected four awards, interested small businesses are encouraged to collaborate and develop responsive projects. Key deadlines include an estimated synopsis post date of February 4, 2026, a close date of April 6, 2026, and an anticipated award date of December 4, 2026. For further inquiries, applicants can contact Heiyoung Park, Ph.D., at Heiyoung.Park@nih.gov or by phone at 301-827-5992.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.
    Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Resource-Related Research Projects aimed at developing models and methodologies for studying human health and diseases, specifically through the R24 grant mechanism, which does not allow clinical trials. This initiative, led by the Office of Research Infrastructure Programs (ORIP), seeks applications that focus on creating broadly applicable research models or new approach methodologies (NAMs) that address diseases impacting multiple organ systems, with a requirement that projects demonstrate relevance to two or more NIH Institutes or Centers. The NIH plans to allocate $5 million annually from fiscal years 2026 to 2029, funding at least six awards each year, with a maximum project duration of four years. Interested applicants, excluding foreign organizations, must complete federal registrations prior to submission and can direct inquiries to ORIPDCM@mail.nih.gov.
    NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)" aimed at supporting discrete research projects across various scientific fields, excluding clinical trials. This grant encourages applications from a diverse range of eligible entities, including higher education institutions, nonprofits, and organizations serving underrepresented communities, with the goal of fostering innovative research that enhances public health and scientific knowledge. The funding does not impose limits on application budgets, provided they reflect actual project needs, and allows for a maximum project duration of five years. Interested applicants can find more information and guidelines at the NIH grants website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for January 7, 2028.